nodes	percent_of_prediction	percent_of_DWPC	metapath
Nelarabine—DGUOK—cardiac ventricle—dilated cardiomyopathy	0.0739	0.21	CbGeAlD
Nelarabine—DGUOK—myocardium—dilated cardiomyopathy	0.0695	0.198	CbGeAlD
Nelarabine—DGUOK—heart—dilated cardiomyopathy	0.0485	0.138	CbGeAlD
Nelarabine—DGUOK—cardiac atrium—dilated cardiomyopathy	0.0415	0.118	CbGeAlD
Nelarabine—POLA1—heart—dilated cardiomyopathy	0.0299	0.0851	CbGeAlD
Nelarabine—ADA—heart—dilated cardiomyopathy	0.0278	0.0789	CbGeAlD
Nelarabine—DCK—myocardium—dilated cardiomyopathy	0.0264	0.0752	CbGeAlD
Nelarabine—Adenosine triphosphate—ABCC9—dilated cardiomyopathy	0.0216	1	CrCbGaD
Nelarabine—DCK—heart—dilated cardiomyopathy	0.0185	0.0525	CbGeAlD
Nelarabine—Hypomagnesaemia—Furosemide—dilated cardiomyopathy	0.0178	0.0299	CcSEcCtD
Nelarabine—DCK—cardiac atrium—dilated cardiomyopathy	0.0158	0.0449	CbGeAlD
Nelarabine—Lethargy—Spironolactone—dilated cardiomyopathy	0.0154	0.0258	CcSEcCtD
Nelarabine—Ataxia—Spironolactone—dilated cardiomyopathy	0.0142	0.0238	CcSEcCtD
Nelarabine—Disturbance in attention—Furosemide—dilated cardiomyopathy	0.013	0.0219	CcSEcCtD
Nelarabine—Hypocalcaemia—Furosemide—dilated cardiomyopathy	0.0123	0.0207	CcSEcCtD
Nelarabine—Hyperuricaemia—Furosemide—dilated cardiomyopathy	0.0122	0.0204	CcSEcCtD
Nelarabine—Blood uric acid increased—Furosemide—dilated cardiomyopathy	0.0115	0.0193	CcSEcCtD
Nelarabine—Pleural effusion—Lisinopril—dilated cardiomyopathy	0.0111	0.0186	CcSEcCtD
Nelarabine—Mental disability—Furosemide—dilated cardiomyopathy	0.00979	0.0165	CcSEcCtD
Nelarabine—Lethargy—Furosemide—dilated cardiomyopathy	0.00836	0.014	CcSEcCtD
Nelarabine—Wheezing—Lisinopril—dilated cardiomyopathy	0.00822	0.0138	CcSEcCtD
Nelarabine—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00811	0.0136	CcSEcCtD
Nelarabine—Neuropathy—Lisinopril—dilated cardiomyopathy	0.00795	0.0134	CcSEcCtD
Nelarabine—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00767	0.0129	CcSEcCtD
Nelarabine—Dehydration—Furosemide—dilated cardiomyopathy	0.00761	0.0128	CcSEcCtD
Nelarabine—Confusional state—Spironolactone—dilated cardiomyopathy	0.00746	0.0125	CcSEcCtD
Nelarabine—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00745	0.0125	CcSEcCtD
Nelarabine—Hypertonia—Lisinopril—dilated cardiomyopathy	0.00742	0.0125	CcSEcCtD
Nelarabine—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00724	0.0122	CcSEcCtD
Nelarabine—Muscular weakness—Furosemide—dilated cardiomyopathy	0.00722	0.0121	CcSEcCtD
Nelarabine—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00712	0.012	CcSEcCtD
Nelarabine—Somnolence—Spironolactone—dilated cardiomyopathy	0.00658	0.0111	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00639	0.0107	CcSEcCtD
Nelarabine—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00638	0.0107	CcSEcCtD
Nelarabine—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.00629	0.0106	CcSEcCtD
Nelarabine—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.00614	0.0103	CcSEcCtD
Nelarabine—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00614	0.0103	CcSEcCtD
Nelarabine—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.0061	0.0102	CcSEcCtD
Nelarabine—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00597	0.01	CcSEcCtD
Nelarabine—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00585	0.00983	CcSEcCtD
Nelarabine—Ataxia—Lisinopril—dilated cardiomyopathy	0.00578	0.00971	CcSEcCtD
Nelarabine—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00576	0.00968	CcSEcCtD
Nelarabine—Dehydration—Lisinopril—dilated cardiomyopathy	0.00571	0.0096	CcSEcCtD
Nelarabine—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00559	0.0094	CcSEcCtD
Nelarabine—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00555	0.00933	CcSEcCtD
Nelarabine—DGUOK—Purine metabolism—GPX1—dilated cardiomyopathy	0.00533	0.168	CbGpPWpGaD
Nelarabine—Eye disorder—Furosemide—dilated cardiomyopathy	0.00529	0.0089	CcSEcCtD
Nelarabine—Angiopathy—Furosemide—dilated cardiomyopathy	0.00514	0.00864	CcSEcCtD
Nelarabine—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00506	0.00851	CcSEcCtD
Nelarabine—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00496	0.00835	CcSEcCtD
Nelarabine—Malnutrition—Furosemide—dilated cardiomyopathy	0.00493	0.00829	CcSEcCtD
Nelarabine—Dizziness—Spironolactone—dilated cardiomyopathy	0.00489	0.00822	CcSEcCtD
Nelarabine—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00483	0.00812	CcSEcCtD
Nelarabine—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00479	0.00805	CcSEcCtD
Nelarabine—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00476	0.00801	CcSEcCtD
Nelarabine—Depression—Lisinopril—dilated cardiomyopathy	0.00472	0.00794	CcSEcCtD
Nelarabine—Vomiting—Spironolactone—dilated cardiomyopathy	0.0047	0.00791	CcSEcCtD
Nelarabine—Vision blurred—Furosemide—dilated cardiomyopathy	0.00465	0.00781	CcSEcCtD
Nelarabine—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00464	0.0078	CcSEcCtD
Nelarabine—Headache—Spironolactone—dilated cardiomyopathy	0.00463	0.00779	CcSEcCtD
Nelarabine—Anaemia—Furosemide—dilated cardiomyopathy	0.00456	0.00766	CcSEcCtD
Nelarabine—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00448	0.00753	CcSEcCtD
Nelarabine—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00447	0.00751	CcSEcCtD
Nelarabine—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00444	0.00747	CcSEcCtD
Nelarabine—Leukopenia—Furosemide—dilated cardiomyopathy	0.00441	0.00742	CcSEcCtD
Nelarabine—Nausea—Spironolactone—dilated cardiomyopathy	0.00439	0.00739	CcSEcCtD
Nelarabine—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.0042	0.00706	CcSEcCtD
Nelarabine—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00419	0.00704	CcSEcCtD
Nelarabine—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00417	0.007	CcSEcCtD
Nelarabine—Confusional state—Furosemide—dilated cardiomyopathy	0.00406	0.00682	CcSEcCtD
Nelarabine—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00395	0.00663	CcSEcCtD
Nelarabine—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00394	0.00662	CcSEcCtD
Nelarabine—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00386	0.00648	CcSEcCtD
Nelarabine—Anorexia—Furosemide—dilated cardiomyopathy	0.00384	0.00645	CcSEcCtD
Nelarabine—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00383	0.00644	CcSEcCtD
Nelarabine—Chills—Lisinopril—dilated cardiomyopathy	0.00381	0.00641	CcSEcCtD
Nelarabine—Hypotension—Furosemide—dilated cardiomyopathy	0.00376	0.00632	CcSEcCtD
Nelarabine—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00372	0.00626	CcSEcCtD
Nelarabine—Malnutrition—Lisinopril—dilated cardiomyopathy	0.0037	0.00622	CcSEcCtD
Nelarabine—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00362	0.00609	CcSEcCtD
Nelarabine—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00361	0.00608	CcSEcCtD
Nelarabine—Back pain—Lisinopril—dilated cardiomyopathy	0.00358	0.00602	CcSEcCtD
Nelarabine—Somnolence—Furosemide—dilated cardiomyopathy	0.00358	0.00601	CcSEcCtD
Nelarabine—Decreased appetite—Furosemide—dilated cardiomyopathy	0.0035	0.00588	CcSEcCtD
Nelarabine—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00349	0.00586	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00347	0.00584	CcSEcCtD
Nelarabine—Fatigue—Furosemide—dilated cardiomyopathy	0.00347	0.00583	CcSEcCtD
Nelarabine—Tremor—Lisinopril—dilated cardiomyopathy	0.00347	0.00583	CcSEcCtD
Nelarabine—Pain—Furosemide—dilated cardiomyopathy	0.00344	0.00579	CcSEcCtD
Nelarabine—Constipation—Furosemide—dilated cardiomyopathy	0.00344	0.00579	CcSEcCtD
Nelarabine—Anaemia—Lisinopril—dilated cardiomyopathy	0.00342	0.00575	CcSEcCtD
Nelarabine—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00332	0.00558	CcSEcCtD
Nelarabine—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00331	0.00557	CcSEcCtD
Nelarabine—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00329	0.00553	CcSEcCtD
Nelarabine—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00325	0.00547	CcSEcCtD
Nelarabine—Cough—Lisinopril—dilated cardiomyopathy	0.00323	0.00543	CcSEcCtD
Nelarabine—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00318	0.00535	CcSEcCtD
Nelarabine—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00318	0.00535	CcSEcCtD
Nelarabine—Myalgia—Lisinopril—dilated cardiomyopathy	0.00315	0.0053	CcSEcCtD
Nelarabine—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00315	0.0053	CcSEcCtD
Nelarabine—Chest pain—Lisinopril—dilated cardiomyopathy	0.00315	0.0053	CcSEcCtD
Nelarabine—Confusional state—Lisinopril—dilated cardiomyopathy	0.00304	0.00512	CcSEcCtD
Nelarabine—Oedema—Lisinopril—dilated cardiomyopathy	0.00302	0.00508	CcSEcCtD
Nelarabine—Infection—Lisinopril—dilated cardiomyopathy	0.003	0.00504	CcSEcCtD
Nelarabine—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00296	0.00497	CcSEcCtD
Nelarabine—Asthenia—Furosemide—dilated cardiomyopathy	0.00289	0.00485	CcSEcCtD
Nelarabine—Anorexia—Lisinopril—dilated cardiomyopathy	0.00288	0.00484	CcSEcCtD
Nelarabine—Hypotension—Lisinopril—dilated cardiomyopathy	0.00282	0.00474	CcSEcCtD
Nelarabine—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00275	0.00463	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00275	0.00462	CcSEcCtD
Nelarabine—Insomnia—Lisinopril—dilated cardiomyopathy	0.00273	0.00459	CcSEcCtD
Nelarabine—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00271	0.00456	CcSEcCtD
Nelarabine—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00269	0.00453	CcSEcCtD
Nelarabine—Somnolence—Lisinopril—dilated cardiomyopathy	0.00268	0.00451	CcSEcCtD
Nelarabine—DGUOK—Nucleotide metabolism—GPX1—dilated cardiomyopathy	0.00268	0.0846	CbGpPWpGaD
Nelarabine—Dizziness—Furosemide—dilated cardiomyopathy	0.00266	0.00447	CcSEcCtD
Nelarabine—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00262	0.00441	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00261	0.00438	CcSEcCtD
Nelarabine—Fatigue—Lisinopril—dilated cardiomyopathy	0.0026	0.00438	CcSEcCtD
Nelarabine—Constipation—Lisinopril—dilated cardiomyopathy	0.00258	0.00434	CcSEcCtD
Nelarabine—Pain—Lisinopril—dilated cardiomyopathy	0.00258	0.00434	CcSEcCtD
Nelarabine—Vomiting—Furosemide—dilated cardiomyopathy	0.00256	0.0043	CcSEcCtD
Nelarabine—Headache—Furosemide—dilated cardiomyopathy	0.00252	0.00424	CcSEcCtD
Nelarabine—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00249	0.00418	CcSEcCtD
Nelarabine—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00247	0.00415	CcSEcCtD
Nelarabine—Nausea—Furosemide—dilated cardiomyopathy	0.00239	0.00402	CcSEcCtD
Nelarabine—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00239	0.00401	CcSEcCtD
Nelarabine—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00239	0.00401	CcSEcCtD
Nelarabine—ADA—Circadian rythm related genes—SIK1—dilated cardiomyopathy	0.00238	0.0752	CbGpPWpGaD
Nelarabine—Asthenia—Lisinopril—dilated cardiomyopathy	0.00217	0.00364	CcSEcCtD
Nelarabine—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00207	0.00347	CcSEcCtD
Nelarabine—Dizziness—Lisinopril—dilated cardiomyopathy	0.002	0.00336	CcSEcCtD
Nelarabine—Vomiting—Lisinopril—dilated cardiomyopathy	0.00192	0.00323	CcSEcCtD
Nelarabine—Headache—Lisinopril—dilated cardiomyopathy	0.00189	0.00318	CcSEcCtD
Nelarabine—Nausea—Lisinopril—dilated cardiomyopathy	0.00179	0.00302	CcSEcCtD
Nelarabine—ADA—Purine metabolism—GPX1—dilated cardiomyopathy	0.00177	0.0559	CbGpPWpGaD
Nelarabine—DCK—Purine metabolism—GPX1—dilated cardiomyopathy	0.00163	0.0516	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—FAS—dilated cardiomyopathy	0.00112	0.0353	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—ANKRD1—dilated cardiomyopathy	0.00105	0.0333	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—TAZ—dilated cardiomyopathy	0.00099	0.0313	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—SDHA—dilated cardiomyopathy	0.000896	0.0283	CbGpPWpGaD
Nelarabine—ADA—Nucleotide metabolism—GPX1—dilated cardiomyopathy	0.000889	0.0281	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00088	0.0278	CbGpPWpGaD
Nelarabine—ADA—p73 transcription factor network—FAS—dilated cardiomyopathy	0.000824	0.026	CbGpPWpGaD
Nelarabine—DCK—Nucleotide metabolism—GPX1—dilated cardiomyopathy	0.00082	0.0259	CbGpPWpGaD
Nelarabine—POLA1—Mitotic M-M/G1 phases—EMD—dilated cardiomyopathy	0.000623	0.0197	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—TUBB—dilated cardiomyopathy	0.000523	0.0165	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—TUBB—dilated cardiomyopathy	0.000467	0.0148	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—EMD—dilated cardiomyopathy	0.000466	0.0147	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—RAF1—dilated cardiomyopathy	0.000457	0.0145	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—ALMS1—dilated cardiomyopathy	0.000438	0.0138	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—EMD—dilated cardiomyopathy	0.000417	0.0132	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—ALMS1—dilated cardiomyopathy	0.000392	0.0124	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.00039	0.0123	CbGpPWpGaD
Nelarabine—POLA1—Mitotic M-M/G1 phases—TMPO—dilated cardiomyopathy	0.00037	0.0117	CbGpPWpGaD
Nelarabine—ADA—Metabolism—ANKRD1—dilated cardiomyopathy	0.00035	0.011	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—RAF1—dilated cardiomyopathy	0.000335	0.0106	CbGpPWpGaD
Nelarabine—ADA—Metabolism—TAZ—dilated cardiomyopathy	0.000329	0.0104	CbGpPWpGaD
Nelarabine—DCK—Metabolism—ANKRD1—dilated cardiomyopathy	0.000323	0.0102	CbGpPWpGaD
Nelarabine—POLA1—Mitotic M-M/G1 phases—LMNA—dilated cardiomyopathy	0.000304	0.00961	CbGpPWpGaD
Nelarabine—DCK—Metabolism—TAZ—dilated cardiomyopathy	0.000303	0.00958	CbGpPWpGaD
Nelarabine—ADA—Metabolism—SDHA—dilated cardiomyopathy	0.000297	0.00939	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000285	0.009	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—TMPO—dilated cardiomyopathy	0.000277	0.00875	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000275	0.00867	CbGpPWpGaD
Nelarabine—DCK—Metabolism—SDHA—dilated cardiomyopathy	0.000274	0.00867	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000269	0.0085	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—TMPO—dilated cardiomyopathy	0.000248	0.00783	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—GPX1—dilated cardiomyopathy	0.000243	0.00769	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—CD36—dilated cardiomyopathy	0.000237	0.00748	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—LMNA—dilated cardiomyopathy	0.000228	0.00719	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—AGT—dilated cardiomyopathy	0.000213	0.00674	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—LMNA—dilated cardiomyopathy	0.000203	0.00643	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000179	0.00564	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000122	0.00387	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000117	0.00368	CbGpPWpGaD
Nelarabine—ADA—Metabolism—GPX1—dilated cardiomyopathy	8.08e-05	0.00255	CbGpPWpGaD
Nelarabine—ADA—Metabolism—CD36—dilated cardiomyopathy	7.86e-05	0.00248	CbGpPWpGaD
Nelarabine—DCK—Metabolism—GPX1—dilated cardiomyopathy	7.45e-05	0.00235	CbGpPWpGaD
Nelarabine—DCK—Metabolism—CD36—dilated cardiomyopathy	7.26e-05	0.00229	CbGpPWpGaD
Nelarabine—ADA—Metabolism—AGT—dilated cardiomyopathy	7.08e-05	0.00224	CbGpPWpGaD
Nelarabine—DCK—Metabolism—AGT—dilated cardiomyopathy	6.54e-05	0.00206	CbGpPWpGaD
